Literature DB >> 27267996

Fabrication and evaluation of nanoparticle-assembled BSA microparticles for enhanced liver delivery of glycyrrhetinic acid.

Wenping Wang1,2,3, Yaya Lei1, Hong Sui1,2,3, Wenping Zhang4, Rongyue Zhu1, Jun Feng1, Hong Wang4.   

Abstract

The aim of the present study was to prepare and evaluate microparticle formulation encapsulated with glycyrrhetinic acid (GA) based on bovine serum albumin (BSA). The drug-loaded nanoparticles were firstly formed by a simple desolvation method, and were further assembled into microparticles using zinc chloride and glutaraldehyde as crosslinkers. The obtained microparticles contained approximately 30% (w/w) drug and showed as spherical particles with a size of about 2 μm. Differential scanning calorimetry (DSC) and X-ray powder diffraction (XRPD) analysis indicated that GA lost its crystallinity during the nano/microencapsulation process. In vitro dissolution study demonstrated a typical sustained-release pattern for 24 h with a burst of 28.1% at the first 30 min, which fitted well by Higuchi model. After intravenous administration into mice, the microparticle formulation remained a higher drug level than the solution formulation in blood and liver for more than 18 h. These results suggested the potential benefit of using the prepared albumin microparticles as a promising vector for enhanced liver delivery of poorly water-soluble drug.

Entities:  

Keywords:  Biodistribution; bovine serum albumin; glycyrrhetinic acid; liver targeting; microparticles; nanoparticles

Mesh:

Substances:

Year:  2016        PMID: 27267996     DOI: 10.1080/21691401.2016.1193024

Source DB:  PubMed          Journal:  Artif Cells Nanomed Biotechnol        ISSN: 2169-1401            Impact factor:   5.678


  1 in total

1.  ROS-responsive 18β-glycyrrhetic acid-conjugated polymeric nanoparticles mediate neuroprotection in ischemic stroke through HMGB1 inhibition and microglia polarization regulation.

Authors:  Lulu Jin; Zhixin Zhu; Liangjie Hong; Zhefeng Qian; Fang Wang; Zhengwei Mao
Journal:  Bioact Mater       Date:  2022-04-01
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.